Angeline Nanni is the CEO, President of UMED Pharmaceuticals, LLC. She has over 15 years of experience in the pharmaceutical industry in global market access strategies, traveling globally to over 45 countries, for life-saving interventions. Recently, Ms. Nanni was the Director of Global Access at Aeras, a non-profit biotech company working in research and development for new tuberculosis vaccines; she led the effort to ensure access of tuberculosis vaccines from research and development to worldwide markets for maximum public health impact.
As a public health consultant, Ms. Nanni worked closely with the Bill & Melinda Gates Foundation in policy and finance, developing a private sector strategy and a roadmap to identify barriers to access to medicines for the poorest countries, Previously Ms. Nanni was the Director of Vaccine Finance and Supply for the Pneumococcal Accelerated Development and Introduction Plan (PneumoADIP) at the Johns Hopkins Bloomberg School of Public Health, Department of International Health.
Ms. Nanni holds a Master of Business Administration degree and received a Master of Science degree in Applied Behavioral Science from Johns Hopkins University Carey School of Business.